Galapagos NV (NASDAQ:GLPG) Q1 2024 Results Conference Call May 3, 2024 8:00 AM ET
Company Participants
Sofie Van Gijsel - Investor Relations
Paul Stoffels - Chief Executive Officer
Thad Huston - Chief Financial Officer and Chief Operating Officer
Jeevan Shetty - Head of Development Oncology
Conference Call Participants
Xian Deng - UBS
Philip Nadeau - TD Cowen
Nevin Varghese - RBC Capital Markets
Judah Frommer - Morgan Stanley
Jason Gerberry - Bank of America
Jacob Mekhael - KBC Securities
Sean McCutcheon - Raymond James
Sebastiaan van der Schoot - VLK
Shan Hama - Jefferies
Sofie Van Gijsel
Welcome all to the audio webcast of Galapagos' Q1 2024 Results. I'm Sofie Van Gijsel, Investor Relations representing the reporting team at Galapagos. This recorded webcast is accessible via the Galapagos website homepage and will be available for download and replay later on today.
I would like to remind everyone that we will be making forward-looking statements during today's webcast. These forward-looking statements include remarks concerning future developments of the pipeline and our company and possible changes in the industry and competitive environment. Because these forward-looking statements involve risks and uncertainties, Galapagos' actual results may differ materially from the results expressed or implied in these statements.
Today's speakers will be Paul Stoffels, CEO; and Thad Huston, CFO and COO. Paul will reflect on the first quarter of 2024 and present the corporate update. Thad will provide an operational update and go over the financial results. He will also discuss the outlook for 2024 and present concluding remarks.
You will see a presentation on screen. We estimate that the prepared remarks will take about 20 minutes. Then we'll open it up to Q&A with Paul and Thad, joined by Jeevan Shetty, Head of Development Oncology.
And with that, I'll now turn it over to Paul.
Paul Stoffels
Eve, and thank you all for joining for today's webcast. I would like to take a minute to start with our foundation, our vision and mission, which we presented shortly after I joined Galapagos in 2022 and which informs all we do.
We aim to transform patient outcomes through life-changing science and innovation for more years of life and quality of life. And the vision is to eventually reach patients around the world. To that aim, we accelerate transformation innovation through the pursuit of groundbreaking science and collaborations with industry and scientific partners.
Since I joined a little over two years ago, we went through a very important company transformation. And with the recent transfer of Jyseleca business to Alfasigma, we have transformed Galapagos into a pure-play biotech with a revitalized pipeline and put in place the tools we need to meet our future growth ambitions.